Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, November 29, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
New Device Could Make Large Biological Circuits Practical
Innovation from MIT could allow many biological components to be connected to produce predictable effects.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
New Test Developed at Dana-Farber/Brigham and Women's Cancer Center
Rapid Heme Panel - A high-tech genetic test that speeds treatment decisions for blood cancer patients.
Researchers Silence Leading Cancer-Causing Gene
A novel siRNA-based molecule successfully targets KRAS, a well-studied but hard to halt protein important for cancer development and metastasis.
Tumor Suppressor Also Inhibits Key Property Of Stem Cells
The retinoblastoma protein inhibits cancer by controlling cell division. Now, researchers have shown that it also binds to and inhibits genes necessary for pluripotency.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Next-Gen Melanoma Drug Excels in Lab Tests
Anti-cancer activity was reported in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733.
Study Identifying Cell of Origin for Large, Disfiguring Nerve Tumors
Lays groundwork for development of new therapies.
Scroll Up
Scroll Down
Return
Non Viral Reagent for Efficient siRNA Delivery
Anne-Laure Bolcato-Bellemin, In vivo Research Manager, Polyplus-transfection, speaking at RNAi World Congress 2009
Date Posted: Monday, November 02, 2009
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes
Polyplus-transfection SA, a privately-held company developing innovative solutions for the delivery of nucleic acids in research, bioproduction and therapy, announced today that it has granted Roche Glycart AG, a Swiss biotechnology company fully-owned by Roche, a non exclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes.
Monday, January 24, 2011
Genethon to Use Polyplus-transfection’s jetPEI™ Transfection Reagent for Producing Viral Vectors
Genethon will use the jetPEI transfection reagent in the process of developing gene therapies for the treatment of rare diseases.
Friday, September 10, 2010
Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds
New money will fund the company’s RNAplus research program and strengthen its human and material resources.
Friday, December 11, 2009
Polyplus-transfection Unveils Technology to Improve Intracellular Delivery of Small Interfering RNAs In-vivo
The "Sticky siRNA" technology is already being tested in vivo by academic laboratories and biotech companies.
Friday, April 25, 2008
 
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv